Summit Therapeutics Inc. Profit Loss Before Tax
Summit Therapeutics Inc. (SMMT) reported Profit Loss Before Tax of -GBP 5.98 million for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Notes
ifrs-full:ProfitLossBeforeTax · last filed 2020-06-02
- Summit Therapeutics Inc. profit loss before tax for the quarter ending 2020-03-31 was -5.98M GBP.
- Summit Therapeutics Inc. profit loss before tax for the quarter ending 2019-10-31 was -7.76M GBP.
- Summit Therapeutics Inc. profit loss before tax for the quarter ending 2019-07-31 was -6.22M GBP, a 122.93% decline year-over-year.
- Summit Therapeutics Inc. profit loss before tax for the quarter ending 2019-04-30 was -4.87M GBP.
| Period end | Profit Loss Before Tax 3 month | Profit Loss Before Tax 3 month as first filed | Profit Loss Before Tax 6 month | Profit Loss Before Tax 6 month as first filed | Profit Loss Before Tax 9 month | Profit Loss Before Tax 9 month as first filed | Profit Loss Before Tax 11 month | Profit Loss Before Tax 12 month | Profit Loss Before Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | -5.98M GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-12-31 | -25.56M GBP 20-F · filed 2020-04-30 | ||||||||
| 2019-10-31 | -7.76M GBP 6-K · filed 2019-12-17 | -13.98M GBP derived: sum of 2 quarters · filed 2019-12-17 | -18.84M GBP 6-K · filed 2019-12-17 | ||||||
| 2019-07-31 | -6.22M GBP 6-K · filed 2019-10-11 | -11.09M GBP 6-K · filed 2019-10-11 | |||||||
| 2019-04-30 | -4.87M GBP 6-K · filed 2019-06-12 | ||||||||
| 2019-03-31 | -6.17M GBP 6-K · filed 2020-06-02 | ||||||||
| 2019-01-31 | -5.93M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -15.34M GBP derived: sum of 2 quarters · filed 2020-04-30 | 11.78M GBP derived: sum of 3 quarters · filed 2020-04-30 | 4.99M GBP 20-F · filed 2020-04-30 | 5.03M GBP 20-F · filed 2019-03-29 | ||||
| 2018-10-31 | -9.41M GBP 6-K · filed 2019-12-17 | -9.40M GBP 6-K · filed 2018-12-11 | 17.72M GBP derived: sum of 2 quarters · filed 2019-12-17 | 10.93M GBP 6-K · filed 2019-12-17 | 10.96M GBP 6-K · filed 2018-12-11 | -126.00K GBP derived: sum of 4 quarters · filed 2020-04-30 | |||
| 2018-07-31 | 27.13M GBP 6-K · filed 2019-10-11 | 27.14M GBP 6-K · filed 2018-09-20 | 20.34M GBP 6-K · filed 2019-10-11 | 20.36M GBP 6-K · filed 2018-09-20 | 9.28M GBP derived: sum of 3 quarters · filed 2020-04-30 | 6.95M GBP derived: sum of 4 quarters · filed 2020-04-30 | |||
| 2018-04-30 | -6.79M GBP 6-K · filed 2019-06-12 | -6.78M GBP 6-K · filed 2018-06-05 | -17.84M GBP derived: sum of 2 quarters · filed 2020-04-30 | -20.18M GBP derived: sum of 3 quarters · filed 2020-04-30 | -24.74M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||||
| 2018-01-31 | -11.05M GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -13.39M GBP derived: sum of 2 quarters · filed 2020-04-30 | -17.96M GBP derived: sum of 3 quarters · filed 2020-04-30 | -23.92M GBP 20-F · filed 2020-04-30 | -10.89M GBP 20-F · filed 2018-04-13 | ||||
| 2017-10-31 | -2.34M GBP 6-K · filed 2018-12-11 | -6.90M GBP derived: sum of 2 quarters · filed 2018-12-11 | -12.87M GBP 6-K · filed 2018-12-11 | ||||||
| 2017-07-31 | -4.56M GBP 6-K · filed 2018-09-20 | -10.53M GBP 6-K · filed 2018-09-20 | |||||||
| 2017-04-30 | -5.96M GBP 6-K · filed 2018-06-05 | ||||||||
| 2017-01-31 | -25.71M GBP 20-F · filed 2019-03-29 | ||||||||
| 2016-01-31 | -23.20M GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |